Scleroderma - Pathophysiology

European Journal of Dermatology

Volumn 19, Issue 1, 2009, Pages 14-24

  Yamamoto, Toshiyuki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Animal model; Fibroblast; Pathogenesis; Scleroderma

Indexed keywords

AUTOANTIBODY; BLEOMYCIN; BOSENTAN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPHOSPHAMIDE; ENDOTHELIN 1; GAMMA INTERFERON; ILOPROST; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA ANTIBODY; RELAXIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD VESSEL INJURY; CHROMOSOME 15; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MODEL; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOLOGY; LUNG FIBROSIS; MICROCHIMERISM; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PIGMENT DISORDER; REVIEW; SCLERODERMA; SKIN FIBROBLAST; SKIN TIGHTNESS; SKIN ULCER; ULTRAVIOLET IRRADIATION;

EID: 60549096464     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0570     Document Type: Review

References (164)

1. Krieg T, Meurer M. Systemic scleroderma. Clinical and pathophysiological aspects. J Am Acad Dermatol 1988; 18: 457-81.
2. LeRoy EC. A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 1992; 51: 286-8.
3. Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
4. Masi AT, Rodnan GP, Medsger Jr. TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
5. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
6. LeRoy EC, Medsger Jr. TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
7. Yamamoto T, Sawada Y, Katayama I, et al. Local expression and systemic release of stem cell factor in systemic sclerosis with diffuse hyperpigmentation. Br J Dermatol 2001; 144: 199-200.
8. Siracusa LD, McGrath R, Ma Q, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996; 6: 300-13.
9. Tan FK, Wang N, Kuwana M, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctow and Japanese population. Arthritis Rheum 2001; 44: 893-901.
10. Hata R, Akai J, Kimura A, et al. Association of functional microsatellites in the human type 1 collagen alpha2 chain (COL1A2) gene with systemic sclerosis. Biochem Biophys Res Commun 2000; 272: 36-40.
11. Crilly A, Hamilton J, Clark CJ, et al. Analysis of transforming growth factor 1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 2002; 61: 678-81.
12. Fonseca C, Lindahl G, Ponticos M, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007; 357: 1210-20.
13. Evans PC, Lambert N, Maloney S, et al. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999; 93: 2033-7.
14. Johnson KL, Nelson JL, Furst DE, et al. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum 2001; 44: 1848-54.
15. Sato S, Fujimoto M, Hasegawa M, et al. Altered blood B lymphocyte homeostasis in systemic sclerosis. Expanded naïve B cells and diminished but activated memory B cells. Arthritis Rheum 2001; 50: 1918-27.
16. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl JMed 2006; 354: 2667-76.
17. Roberts AB, Sporn MB. The transforming growth factor s. In: Sporn MB, Roberts AB, eds. Handbook of experimental pharmacology. Peptide growth factors and their receptors. Vol 95. New York: Springer-Verlag, 1990: 419-72.
18. Obberghen-Schilling EV, Roche NS, Flanders KC, et al. Transforming growth factor 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988; 263: 7741-6.
19. Kawakami T, Ihn H, Xu W, et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47-51.
20. Gruschwitz M, Muller P, Sepp N, et al. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: A mediator of fibrosis? J Invest Dermatol 1990; 94: 197-203.
21. Kulozik M, Hogg A, Lankat-Buttgereit B, et al. Co-localization of transforming growth factor 2 with 1 (1) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990; 86: 917-22.
22. Peltonen J, Kahari L, Jaakkola S, et al. Evaluation of transforming growth factor and type I procollagen ene expression in fibrotic skin iseases by in situ hybridization. J Invest Dermatol 1990; 94: 365-71.
23. McCormick LL, Zhang Y, Tootell E, et al. Anti-TGF- treatment prevents skin and lung fibrosis in murine sclerodermatous graftversus-host disease: A model for human scleroderma. J Immunol 1999; 163: 5693-9.
24. Yamane K, Ihn H, Kubo M, et al. Increased transcriptional activities of transforming growth factor receptors in scleroderma fibroblasts. Arthritis Rheum 2002; 46: 2421-8.
25. Kubo M, Ihn H, Yamone K, et al. Up-regulated expression of transforming growth factor receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001 44: 73 1-4.
26. Ihn H, Yomane K, Kubo M, et al. Blockade of endogenous transforming growth factor signaling prevents upregulated collopen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor receptors. Arthritis Rheum 2001: 44: 474-80.
27. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthriti's Rheum 2003; 48: 1964-78.
28. Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: A putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99: 3908-13.
29. Asono Y, Ihn H, Yamane K, et al. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-64.
30. Frazier K, Williams S, Kothapalli D, et al. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996; 107: 404-11.
31. Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of connective tissue growth factor gene. Cell Growth Differ 1996; 7: 469-80.
32. Igarashi A, Nashiro K, Kikuchi K, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105: 280-4.
33. Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108: 241-50.
34. Shi-wen X, Pennington D, Holmes A, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000; 259: 213-24.
35. Holmes A, Abraham DJ, Chen Y, et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 2003; 278: 41728-33.
36. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27: 149-54.
37. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, et al. Interleukin (IL)-4 and IL-13 act on human lung fibroblasts. J Clin Invest 1998; 101: 2129-39.
38. Jinnin M, Ihn H, Yamone K, et al. Interleukin-11 3 stimulates the transcription of the human alpha 2(1) collagen gene in human dermal fibroblasts. J Biol Chem 2004; 279: 41783-91.
39. Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-1 3 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000; 292: 988-94.
40. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, et al. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998; 10: 1421-33.
41. Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor 1. J Exp Med 2001; 194: 809-21.
42. Hasegawa M, Fujimoto M, Kikuchi K, et al. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24: 328-32.
43. Riccieri V, Rinaldi T, Spadaro A, et al. Interleukin-13 in systemic sclerosis: Relationship to noilfold capillaroscopy abnormalities. Clin Rheumatol 2003; 22: 102-6.
44. Yamamoto T. Chemokines and chemokine receptor in scleroderma. Int Arch All Immunol 2006; 140: 345-56.
45. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor 1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271: 17779-84.
46. Yamamoto T, Eckes B, Mauch C, et al. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 loop. J Immunol 2000; 164: 6174-9.
47. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-drived growth factor and effects of monocyte chemotaxis and collogen synthesis. Arthritis Rheum 2001; 44: 2665-78.
48. Galindo M, Santiago B, Rivera M, et al. Chemokine expression by systemic sclerosis fibroblasts: Abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001; 44: 1382-6.
49. Hasegawa M, Sato S, Takehara K. Augmentation of production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1) and (MIP-1) in patients with systemic sclerosis: MCP-1 and MIP-1 may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999; 117: 159-65.
50. Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001; 31: 2936-41.
51. Yamamoto T, Eckes B, Hartmann K, et al. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001; 26: 133-9.
52. Zhu Z, Ma B, Zheng T, et al. IL-1 3-induced chemokine responses in the lung: Role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2002; 168: 2953-62.
53. Troutmann A, Toksoy A, Engelhardt E, et al. Mast cell involvement in normal human skin wound healing: Expression of monocyte chemoattractant protein-1 is correlated with recruitment of most cells which synthesize interleukin-1 in vivo. J Pathol 2000; 190: 100-6.
54. Selvan RS, Butterfield JH, Krangel MS. Expression of multiple chemokine genes by human mast cells. J Biol Chem 1994; 269: 13893-8.
55. Yamamoto T, Katayama I, Nishioka K. Expression of stem cell factor in the lesional skin of systemic sclerosis. Dermatology 1998; 197: 109-14.
56. Yamamoto T, Hartmann K, Eckes B, et al. Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fiborosis. J Dermatol Sci 2001; 26: 106-11.
57. Carulli MT, Ong VH, Ponticos OM, et al. Chemokine receptor CCR2 expression b systemic sclerosis fibroblasts: Evidence for autocrine regulation of myofibroblost differentiation. Arthritis Rheum 2005; 52: 3772-82.
58. Zhou L, Azfer A, Niu J, et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res 2006; 98: 1177-85.
59. Karrer S, Bosserhoff AK, Weiderer P, et al. The -2518 promoter Rolymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005; 124: 92-8.
60. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-316.
61. Yamakage A, Kikuchi K, Smith EA, et al. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175: 1227-34.
62. Gay S, Jones RE, Huang G, et al. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92: 301-3.
63. Klareskog L, Gustafsson R, Scheynimus A, et al. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990; 33: 1534-40.
64. Xue-yi Z, Jian-Zhong Z, Ping T, et al. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor - receptor in fibroblasts of scleroderma. J Dermatol Sci 1998; 18: 90-7.
65. Makhluf HA, Stepniakowska J, Hoffman S, et al. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol 1996; 107: 856-9.
66. Ihn H, Yamane K, Asano Y, et al. IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase-dependent pathway. J Immunol 2002; 168: 1895-902.
67. Elovic AE, Ohyama H, Sauty A, et al. IL-4-dependent regulation of TGF-alpha and TGF-beta 1 expression in human eosinophils. J Immunol 1998; 160: 6121-7.
68. Seder RA, Marth T, Sieve MC, et al. Factors involved in the differentiation of TGF-beta-producin cells from naive CD4+ T cells: IL-A and IFN-gamma have opposite effects, while TGF-beta positively regulates its own production. J Immunol 1998; 160: 5719-28.
69. Needlemann BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor, and interferon- levels in sera from patients with scleroderma. Arthritis Rheum 1985; 28: 775-80.
70. Serpier H, Gillery P, Salmon-Ehr V, et al. Antagonistic effect of interferon-gamma and interleukin-4 on fibroblast cultures. J Invest Dermatol 1997; 109: 158-62.
71. Kurasawa K, Hirose K, Sano H, et al. increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
72. Pesce J, Kaviratne M, Ramalingam TR, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 2006; 116: 2044-55.
73. Distler JH, Jungel A, Kowal-Bielecka O, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005; 52: 856-64.
74. Ihn H, Sato S, Fujimoto M, et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000; 119: 203-9.
75. Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603-10.
76. Horstmeyer A, Licht C, Scherr G, et al. Signaling and regulation of collagen I synthesis by ET-1 and TGF-1. FEBS J 2005; 272: 6297-309.
77. Shephard P, Hinz B, Smola-Hess S, et al. Dissecting the roles of endothelin, TGF- and GM-CSF on myofibroblast differentiation by keratinocytes. Thromb Haemost 2004; 92: 262-74.
78. Shi-wen X, Dnton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. J Invest Dermatol 2001; 116: 417-25.
79. Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets: A marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838-44.
80. Eckes B, Kessler D, Aumailley M, et al. Interactions of fibroblasts with extracellular matrix: implications for the understanding of fibrosis. Springer Semin Immunopathol 1999; 21: 415-29.
81. Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes: Collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36: 598-606.
82. Gailit J, Marchese MJ, Kew RR, et al. The differentiation and function of myofibroblasts is regulated by most cell mediators. J Invest Dermatol 2001; 117: 1113-9.
83. Mahoney JA, Rosen A. Apoptosis and autoimmunity. Curr Opin Immunol 2005; 17: 583-8.
84. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor 1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000; 43: 2230-9.
85. Santiago B, Galindo M, Rivera M, et al. Decreased susceptibility to Fos-induced apoptosis of sistemic sclerosis dermal fibroblasts. Arthritis Rheum 2001; 44: 1667-76.
86. Zhang HY, Phan SH, Inhibition of myofibroblost apoptosis by transforming growth factor beta 1. Am J Respir Cell Mol Biol 1999; 21: 658-65.
87. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary athogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-92.
88. Laplante P, Raymond MA, Gagnon G, et al. Novel fibrogenic pathways are activated in response to endothehal apoptosis: Implications in the athophysiology of systemic sclerosis. J Immunol 2005; 174: 5740-9.
89. Wetzig T, Petri JB, Mittag M, et al. Serum levels of soluble Fas/ APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 1998; 290: 187-90.
90. Stummvoll GH, Aringer M, Smolen JS, et al. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology 2000; 39: 1341-50.
91. Bianchi T, Bardazzi F, Patrizi A. Soluble Fas levels in patients with systemic sclerosis. Arch Dermatol Res 2000; 292: 522-3.
92. Ates A, Kinikli G, Turgay M, et al. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin Rheumatol 2004; 23: 421-5.
93. Kessel A, Rosner I, Rozenbaum M, et al. Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-13. J Clin Immunol 2004; 24: 30-6.
94. Jun JB, Kuechle M, Min J, et al. Scleroderma fibroblasts demonstrate enhanced activation of Akf (protein kinase B) in situ. J Invest Dermatol 2005; 124: 298-303.
95. Sambo P, Jannino L, Candela M, et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999; 112: 78-84.
96. Sambo P, Baroni SS, Luchetti M, et al. Oxidative stress in scleroderma: Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through NADPH oxidase complex pathway. Arthritis Rheum 2001; 44: 2653-64.
97. Murrell GAC, Francis WJO, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 1990; 265: 659-65.
98. Falango V, Martin TA, Takagi H, et al. Low oxygen tension increases mRNA levels of alpha1(l) procollagen in human dermal fibroblasts. J Cell Physiol 199; 157: 408-12.
99. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997; 185: 71-9.
100. Galindo M, Santiago B, Alcami J, et al. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-B in human dermal fibroblasts. Clin Exp Immunol 2001; 123: 36-41.
101. Yamamoto T. Bleomycin and the skin. Br J Dermatol 2006; 155: 869-75.
102. Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62.
103. Yamamoto T, Takahashi Y, Takagawa S, et al. Animal model of sclerotic skin. II: Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/Wv mice. J Rheumatol 1999; 26: 2628-34.
104. Yamamoto T, Kuroda M, Takagawa S, et al. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000; 292: 535-41.
105. Yamamoto T, Nishoka K. Animal model of sclerotic skin. V: Increased expression of -smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002; 102: 77-83.
106. Shibusawa Y, Negishi I, Tabata Y, et al. Mouse model of dermal fibrosis induced by one-time injection of bleomycin-poly(L-lactic acid) microspheres. Rheumatology 2008; 47: 454-7.
107. King SL, Lichtler AC, Rowe DW, et al. Bleomycin stimulates pro 1(l) collagen promoter through transforming growth factor-responce element by intracellular and extracellular signaling. J Biol Chem 1994; 269: 13156-61.
108. Oi M, Yamamoto T, Nishioka K. Increased expression of TGF-1 in the sclerotic skin in bleomycin-'susceptible' mouse strains. J Med Dent Sci 2004; 51: 7-17.
109. Yamamoto T, Takagawa S, Katayama I, et al. Anti-sclerotic effect of anti-transforming growth factor- antibody in bleomycin-induced scleroderma. Clin Immunol 1999; 92: 6-13.
110. Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of pepticle inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermotol 2005; 125: 450-5.
111. Takagawa S, Lakos G, Mori Y, et al. Sustained activation of fibroblast transforming growth factor-/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003; 121: 41-50.
112. Matsushita M, Yamamoto T, Nishicka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch All Immunol 2004; 135: 348-56.
113. Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci 2007; 104: 2827-30.
114. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003; 121: 510-6.
115. Ferreira AM, Takagawa S, Fresco R, et al. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006; 126: 1900-8.
116. Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermotol 2004; 122: 44-50.
117. Yamamoto T, Yokozeki H, Nishioka K. Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma. Arch Dermatol Res 2007; 298: 465-8.
118. Murota H, Hamasaki Y, Nakashima T, et al. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced scleroderma skin fibroblasts. Arthritis Rheum 2003; 48: 1117-25.
119. Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collogen, fibronectin and decorin gene expression in human skin fibroblasts. Arch Dermatol Res 2000; 292: 556-61.
120. Yamamoto T. The bleomycin-induced scleroderma model: What have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006; 297: 333-44.
121. Green LD, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976; 82: 493-507.
122. Pablos JL, Everett ET, Harley R, et al. Transforming growth factor-1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse. Lab Invest 1995; 72: 670-8.
123. Christner PJ, Peters J, Hawkins D, et al. The tight skin 2 mice: An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 1995; 38: 1791-8.
124. Sgonc R, Dietrich H, Sieberer C, et al. Lack of endothelial cell apoptosis in the dermis of tight skin 1 and tight skin 2 mice. Arthritis Rheum 1999; 42: 581-4.
125. MacGaha T, Saito S, Phelps RG, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R and transforming growth factor- genes. J Invest Dermatol 2001, 116: 136-43.
126. Ong CJ, Ip S, Teh SJ, et al. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999; 196: 60-8.
127. Pablos JL, Everett ET, Harley R, et al. Transforming growth factor-1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse. Lab Invest 1995; 72: 670-8.
128. Wang HW, Tedla N, Hunt JE, et al. Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma. Exp Dermatol 2005; 14: 295-302.
129. Phelps RG, Daian C, Shibato S, et al. Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57/BL/6 Pa/Pa mice. J Autoimmun 1993; 6: 701-18.
130. Ong CJ, Ip S, Teh SJ, et al. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999; 196: 60-8.
131. Wallace VA, Kondo S, Kono T, et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in fight skin mice. Eur J Immunol 1994; 24: 1463-6.
132. Walker M, Harley R, LeRoy EC. Inhibition of fibrosis in Tsk mice by blocking most cell degranulation. J Rheumatol 1987; 14: 299-301.
133. Kikuchi H, Hanazawa S, Takeshita A, et al. Interleukin-4 acts as a potent stimulator for expression of monocyte chemoattractant JE/MCP-1 in mouse peritoneal macrophages. Biochem Biophys Res Commun 1993; 203: 562-9.
134. Lee YW, Hennig B, Toborek M. Redox-regulated mechanisms of IL-4-induced MCP-1 expression in human vascular endothelial cells. Am J Physiol Heart Cire Physiol 2003; 284: H185-H192.
135. Lukacs NW, Chensue SW, Karpus WJ, et al. C-C chemokines differentially alter interleukin-4 production from lymphocytes. Am J Pathol 1997; 150: 1861-8.
136. Ong VH, Evans LA, Shiwen X, et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003; 48: 1979-91.
137. Saito E, Fujimoto M, Hasegawa M, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-62.
138. Mccormick LL, Zhang Y, Tootell E, et al. Anti-TGF-treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163: 5693-9.
139. Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2003; 121: 713-9.
140. Zhang Y, Mccormick LL, Desai SR, et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002; 168: 3088-98.
141. Ruzek MC, Jha S, Ledbetter S, et al. A modified model of graft-versus-host induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004; 50: 1319-31.
142. Van De Water J, Gershwin ME. Avian scleroderma. An inherited fibrotic disease of White Leghorn chickens resembling progressive systemic sclerosis. Am J Pathol 1986; 120: 478-82.
143. Gruschwitz MS, Moormann S, Kromer G, et al. Phenotypic analysis of skin infiltrates in comparison with peripheral blood lymphocytes, spleen cells and thymocytes in early avian scleroderma. J Autoimmunity 1991; 4: 577-93.
144. Sgonc R, Gruschwitz MS, Boeck G, et al. Endothelial cell apoptosis in systemic sclerosis is induced bKr antibody-dependent cell-mediated cytotoxicity via CD95. Arthiritis Rheum 2000; 43: 2550-62.
145. Worda M, Sgonc R, Dietrich H, et al. In vivo analysis of the apoptosis-induce effect of anti-endothelial cell antibodies systemic sclerosis by the chorionallantoic membrone assay. Arthritis Rheum 2003; 48: 2605-14.
146. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type: Rapid induction of fibroblasts and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83: 4167-70.
147. Shinozaki M, Kawara S, Hayashi N, et al. Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor-beta-simultaneous application with basic fibroblast growth factor causes persistent fibrosis. Biochem Biophys Res Commun 1997; 237: 292-7.
148. Mori T, Kawara S, Shinozaki M, et al. Role and interaction of connective tissue growth factor with transforming growth factor- in persistent fibrosis: A mouse fibrosis model. J Cell Physiol 1999; 181: 153-9.
149. Takeharo K. Pathogenesis of systemic sclerosis. J Rheumatol 2003; 30: 755-9.
150. Chujo S, Shirasaki F, Kawara S, et al. Connective tissue growth factor causes persistent proalpha2(l) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 2003: 447-56.
151. Ikawa Y, Ng PS, Endo K, et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol 2008 [EPub ahead of print].
152. Denton CP, Zheng B, Evans LA, et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor (TGF) receptor leads to paradoxical activation of TGF signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003; 278: 25109-19.
153. Denton CP, Lindahl GE, Khan K, et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor- receptor (TβRIlk). J Biol Chem 2005; 280: 16053-65.
154. Samuel CS, Zhao C, Yang Q, et al. The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol 2005; 125: 692-9.
155. Khanna D, Clements PJ, Furst DE, et al., for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea score correlates with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592-600.
156. Rosenbloom J, Feldman G, Freundlich B, et al. Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum 1986; 29: 851-6.
157. Ulloa L, Doody-J, Massagué J. Inhibition of transforming growth factor-/SMAD signaling by the interferon-/STAT pathway. Nature 1999; 397: 710-3.
158. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicenter trial. Br J Dermatol 1998; 139: 639-48.
159. Quan T, He T, Kang S, et al. Connective tissue growth factor: Expression in human skin in vivo and inhibition by ultraviolet irradiation. J Invest Dermatol 2002; 118: 402-8.
160. Quan T, He T, Voorhees JJ, et al. Ultraviolet irradiation blocks cellular responses to transforming growth factor- by down-regulating its type-II receptor and inducing SMAD7. J Biol Chem 2001; 276: 26349-56.
161. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blin study. Ann Intern Med 1994; 120: 199-206.
162. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor betal antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-33.
163. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosurpressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term fo[low-up of the multicenter pilot study. Blood 2007; 110: 1388-96.
164. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-93.